Mo Xu, M.D., Ph.D.

With a wealth of experience in the pharmaceutical industry, she has held positions at Gemvax (overseas) and several multinational companies, including AstraZeneca, Merck, MSD, Pfizer, as well as the local pharmaceutical company Alphamab Oncology. In these roles, she has served as Vice President of Clinical Development for various innovative drugs, making significant contributions to clinical research and development in fields such as immune-oncology products, ADC products, and anti-cancer vaccines. Her expertise lies in the development of innovative drugs, and she possesses in-depth knowledge of both domestic and international regulatory requirements, treatment guidelines, as well as strategies for immune-oncology development, market access, and product positioning. She has successfully led teams in the completion of multiple innovative drug development projects, both domestically and internationally. She obtained her doctoral degree from Yonsei University in South Korea.